Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in… EP News Bureau Dec 11, 2024 Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5 per cent;…
